CDK9-IN-22
CDK9-IN-22 is a potent CDK9 inhibitor with IC50s of 10.4, 876.2 nM for CDK9, CDK, respectively. CDK9-IN-22 induces apoptosis and cell cycle arrests at G2/M phase. CDK9-IN-22 decreases the expression of p-RNAPII (S2) and CDK9 protein. CDK9-IN-22 shows antiproliferative and aiti-tumor activity[1].
Product Specifications
CAS Number
2872677-61-5
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk9-in-22.html
Solubility
10 mM in DMSO
Smiles
CN(CCNC(C1=CC=C(C=C1)NC2=NC(C3=C(C=C(C=C3)F)OCC4=CC=CC=C4)=CC=N2)=O)C
Molecular Formula
C28H28FN5O2
Molecular Weight
485.55
References & Citations
[1]Xu Z, et al. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors. Eur J Med Chem. 2022 Dec 15;244:114875.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK2; CDK9
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
VAng-Lsx04496-50gEcoli 50 µg (E. coli)
Recombinant Legionella Pneumophila rlmD Protein (aa 1-444) (strain Lens)
Sign In for Pricing
View Details 
N5380-25A-ML750 100 µL
NR2A (NT) (Grin2a, Glutamate Receptor, ionotropic, NMDA2A (epsilon 1), GluRepsilon1, NMDAR2A, N-methyl D-aspartate Receptor subtype 2A) (MaxLight 750) discontinued
Sign In for Pricing
View Details